Simvastatin; Sitagliptin Phosphate Patent Expiration
Simvastatin; Sitagliptin Phosphate is Used for managing type 2 diabetes mellitus in patients for whom treatment with both sitagliptin and simvastatin is appropriate. It was first introduced by Merck Sharp And Dohme Corp
Simvastatin; Sitagliptin Phosphate Patents
Given below is the list of patents protecting Simvastatin; Sitagliptin Phosphate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Juvisync | US6303661 | Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals |
Apr 24, 2017
(Expired) | Merck Sharp Dohme |
| Juvisync | US6699871 | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul 26, 2022
(Expired) | Merck Sharp Dohme |
| Juvisync |
US6699871 (Pediatric) | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jan 26, 2023
(Expired) | Merck Sharp Dohme |
| Juvisync | US6890898 | Method of regulating glucose metabolism, and reagents related thereto |
Feb 02, 2019
(Expired) | Merck Sharp Dohme |
| Juvisync | US7078381 | Method of regulating glucose metabolism, and reagents related thereto |
Feb 02, 2019
(Expired) | Merck Sharp Dohme |
| Juvisync | US7125873 | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul 26, 2022
(Expired) | Merck Sharp Dohme |
| Juvisync |
US7125873 (Pediatric) | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jan 26, 2023
(Expired) | Merck Sharp Dohme |
| Juvisync | US7326708 | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor | Apr 11, 2026 | Merck Sharp Dohme |
| Juvisync |
US7326708 (Pediatric) | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor | Oct 11, 2026 | Merck Sharp Dohme |
| Juvisync | US7459428 | Method of regulating glucose metabolism, and reagents related thereto |
Feb 02, 2019
(Expired) | Merck Sharp Dohme |
| Juvisync | US8168637 | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment of diabetes |
Jun 26, 2022
(Expired) | Merck Sharp Dohme |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳